Abstract:Background: Hypertensive disorders of pregnancy are a leading cause of maternal and perinatal morbidity and mortality. If women at high risk for developing complications could be identified early, level of care could be triaged, limited resources could be correctly allocated and targeted interventions to prevent complications could be implemented. Methods: We updated a systematic review and meta-analysis and added single outcomes. Women with hypertensive disorders of pregnancy were included. Exposures were tests predicting adverse maternal and/or perinatal outcomes. We searched Medline, Embase, CINAHL, and Cochrane library from January 2016-February 2024. We included studies identified from the previous review. We calculated effect measures. For similar predictive tests and outcomes, area under the receiver-operating-characteristic curve (AUROC) were pooled. This study was registered by PROSPERO: CRD42022336368. Findings: Of the 2898 studies identified, 80 were included. Thirty were added from the previous review resulting in 110 included studies with 506,178 women. Despite more than 1500 tests being performed, most outcomes could not be pooled due to heterogeneity in populations, tests, and outcome definitions. For maternal outcomes, only studies reporting on the Pre-eclampsia Integrated Estimate of RiSk (fullPIERS) model could be pooled. For the composite outcome within 48-h the AUROC was 0.78 (95% CI 0.71-0.86, N = 8). There was significant heterogeneity (I 2 = 95.7%). For perinatal outcomes, data were pooled for pulsatility index in the umbilical artery and soluble FMS-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio. Biomarkers like the sFlt-1/PlGF ratio showed promising predictive performance for some outcomes but were not externally validated. Interpretation: Despite including over 100 studies with more than 1500 predictors, we were unable to pool any single maternal outcomes and only a few individual perinatal outcomes. The fullPIERS model was externally validated, showing moderate accuracy which varied across studies and should be validated in each new population. Angiogenic biomarkers showed promise but need validation. Future studies should use standardized outcome measures and validate promising tests. Funding: VB is supported by the Swedish Research Council, Grant number 2020-01481. University of Gothenburg.

EP17.27: Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of adverse maternal outcomes in women with pre‐eclampsia

EP17.66: Prenatal care strategy using clinical factors for pre‐eclampsia risk prediction and prophylaxis indication

EP17.54: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse neonatal outcome in women with suspected pre‐eclampsia

Study on the Level Changes of N-terminal Pro-B-type Natriuretic Peptide in the Serum of Patients with Pre-eclampsia and Its Clinical Significance

Proteomic Profiles of Maternal Plasma Extracellular Vesicles for Prediction of Preeclampsia

Increased B-type natriuretic peptide levels in early-onset versus late-onset preeclampsia

OP13.05: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse maternal outcome in women with suspected pre‐eclampsia

Serum Levels of N-Terminal Pro-Brain Natriuretic Peptide in Gestational Hypertension, Mild Preeclampsia, and Severe Preeclampsia: A Study from a Center in Zhejiang Province, China

EP08.21: Prediction of adverse intrapartum outcomes at 35–37 weeks

P182 AORTIC VASCULAR BIOMARKERS FOR THE EARLY DETECTION OF PLACENTAL SYNDROMES DURING PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Prediction of adverse maternal and perinatal outcomes associated with pre-eclampsia and hypertensive disorders of pregnancy: a systematic review and meta-analysis

Correlation of 24-h Urinary Protein Excretion, Serum Indicators, and Placental Growth Factor in Patients with Preeclampsia and their Adverse Outcome

Routine ante-natal screening using maternal risk factors and biomarkers for preeclampsia in 11-13+6 weeks of gestation

EP17.24: Maternal ophthalmic artery Doppler in normal pregnancy and pre‐eclampsia and its association with pregnancy outcome

A New Predicting Model of Preeclampsia Based on Peripheral Blood Test Value

Maternal Serum PLGF, PAPPA, Β-Hcg and AFP Levels in Early Second Trimester As Predictors of Preeclampsia

OP15.03: Maternal cardiovascular hemodynamics for the prediction of pre‐eclampsia at 12–16 weeks

High Serum Adrenomedullin and Mid-Regional Pro-Atrial Natriuretic Peptide Concentrations in Early Pregnancy Predict the Development of Gestational Hypertension

Predicting preeclampsia by integrating maternal characteristics, mean arterial pressure and serum biomarkers at 15～20 gestational weeks

Novel Associations Between Mid-Pregnancy Cardiovascular Biomarkers and Preeclampsia: An Explorative Nested Case-Control Study

Maternal Mid-Trimester Placental Growth Factor and Uterine Artery Doppler Velocimetry in Evolution of Pre-Eclampsia